Wikisage, the free encyclopedia of the second generation, is digital heritage
Lennox-Gastaut syndrome: Difference between revisions
(→Clobazam: hide) |
(→Clobazam: epilepsia) |
||
| Line 15: | Line 15: | ||
[http://www.epilepsybehavior.com/article/S1525-5050(15)00044-X/pdf Clobazam is equally safe and efficacious for seizures associated with Lennox–Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results] | [http://www.epilepsybehavior.com/article/S1525-5050(15)00044-X/pdf Clobazam is equally safe and efficacious for seizures associated with Lennox–Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results] | ||
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12561/epdf stable dosage of clobazam for LGS are associated Epilepsia 55: 558(2014)] | |||
{{disease|G40.7|Lennox-Gastaut syndrome}} | {{disease|G40.7|Lennox-Gastaut syndrome}} | ||
Revision as of 22:04, 31 January 2016
Lennox–Gastaut syndrome (LGS) is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life. LGS is characterized by a triad of signs including frequent seizures of multiple types, an abnormal EEG pattern of less than 2.5 Hz slow spike wave activity,[1]
LGS children with a history of perinatal hypoxia or other perinatal event have earlier age of onset of seizures[2]
Links
Endoscopic epilepsy surgery: Emergence of a new procedure
Rufinamide
Clobazam
Clobazam was approved by FDA on 2011 as adjuntive treatment of seisurez associated with LGS in patients 2 year and older [3]
stable dosage of clobazam for LGS are associated Epilepsia 55: 558(2014)
